特瑞普利单抗联合仑伐替尼 TACE治疗晚期肝癌的疗效及对肿瘤标志物预后的影响

doi:10.3969/j.issn.1006-6233.2024.10.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1218 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the efficacy of toripalimab combined with lenvatinib and transarterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma (HCC) and analyze its effects on tumor markers and prognosis. Methods: A total of 108 patients with advanced HCC admitted to the Affiliated Hospital of Xiangya School of Medicine, Central South University (Changde First People's Hospital) from January 2022 to March 2023 were selected and randomly divided into two groups: the study group and the control group, with 54 patients in each group. The control group received lenvatinib + TACE treatment, while the study group received toripalimab + lenvatinib + TACE treatment. Each treatment course lasted 21 days, and three consecutive courses were administered. The treatment efficacy and adverse reactions were compared between the two groups after three courses. Tumor markers [Golgi protein 73 (GP73), carcinoembryonic antigen (CEA), tumor-specific growth factor (TSGF), carbohydrate antigen 19-9 (CA19-9)], immune function (T lymphocyte subsets), serum factors [interleukin-1β (IL-1β), alpha-2-HS-glycoprotein (AHSG), nuclear factor kappa B (NF-κB), soluble epidermal growth factor receptor 3 (sErbB3)], quality of life [FACT-G (Functional Assessment of Cancer Therapy-General) score], and functional status [Karnofsky Performance Status (KPS) score] were compared before and after treatment. Prognosis was assessed within one year after treatment in both groups. Results: The objective response rate (ORR) of the study group was significantly higher than that of the control group (59.26% vs. 37.04%, χ²=5.341, P=0.021). After treatment, serum levels of GP73, CEA, TSGF, and CA19-9 in the study group were significantly lower than those in the control group [(198.62±61.79) ng/mL, (20.45±2.48) ng/mL, (62.08±7.12) U/mL, (26.07±3.49) U/mL vs. (237.91±66.35) ng/mL, (25.63±2.79) ng/mL, (70.61±7.59) U/mL, (29.58±3.86) U/mL, P<0.05]. The levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the study group were significantly higher than in the control group (P<0.05). Serum levels of IL-1β, AHSG, NF-κB, and sErbB3 in the study group were lower than those in the control group [(15.88±3.64) pg/mL, (9.39±3.13) ng/mL, (175.49±38.62) ng/L, (2791.36±256.84) ng/mL vs. (20.56±4.37) pg/mL, (11.72±3.41) ng/mL, (212.83±43.57) ng/L, (2983.49±268.07) ng/mL, P<0.05]. FACT-G and KPS scores were higher in the study group than in the control group after treatment (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). The 1-year survival rate in the study group was 29.63%, significantly higher than the 18.52% in the control group (P<0.05). Conclusion: Toripalimab combined with lenvatinib and TACE has a significant therapeutic effect on advanced hepatocellular carcinoma. It can reduce tumor marker levels, improve immune function and the tumor microenvironment, enhance the quality of life and functional status, and increase the survival rate, with good safety.

Key words： Hepatocellular carcinoma Lenvatinib Transarterial chemoembolization Toripalimab Tumor markers

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.10.030 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I10/1745

[1] Fanoodi A,Maharati A,Akhlaghipour I,et al.MicroRNAs as the critical regulators of tumor angiogenesis in liver cancer[J].Pathol Res Pract,2023,251(1):154913-154923.
[2] Dang ZF,Jiang LW,Huang FP.Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients[J].Int Clin Pharmacol Ther,2023,61(10):423-429.
[3] Ning SK,Li X,Ma XY,et al.Efficacy of TACE combined with lenvatinib plus sintilimab for hepatocellular carcinoma with tumor thrombus in the inferior vena cava and/or right atrium[J].Hepatocell Carcinoma,2023,10(13):1511-1525.
[4] Chen JY,Huang NS,Wei WJ,et al.The efficacy and safety of surufatinib combined with anti PD-1 antibody toripalimab in neoadjuvant treatment of locally advanced differentiated thyroid cancer: a phase Ⅱ study[J].Ann Surg Oncol,2023,30(12):7172-7180.
[5] Liu FR,Liao ZB,Zhang ZG.MYC in liver cancer: mechanisms and targeted therapy opportunities[J].Oncogene,2023,42(45):3303-3318.
[6] Lin RF,Fu XY,Huang JH.Relationship between changes of serum vascular endothelial growth factor and folate receptor-α levels and clinical efficacy of toripalimab in patients with bladder cancer[J].Arch Esp Urol,2024,77(1):31-37.
[7] Mariani P,Torossian N,Van Laere S,et al.Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases[J].Br Cancer,2023,129(5):772-781.
[8] Zhang C,Li Q,Xu Q,et al.Pulmonary interleukin 1 beta/serum amyloid A3 axis promotes lung metastasis of hepatocellular carcinoma by facilitating the pre-metastatic niche formation[J].Exp Clin Cancer Res,2023,42(1):166-176.
[9] Xing XY,Cao FM,Gao LP,et al.AHSG,a gene promoting tumour proliferation,migration and invasion,is an independent prognostic factor for poor overall survival in lung adenocarcinoma[J].Mol Biol Rep,2023,50(9):7659-7666.